Tocilizumab-Associated Small Bowel Perforation in a Young Patient With Rheumatoid Arthritis: A Lesson to Remember During COVID-19 Pandemic.
| Autor: | Saad E; Department of Internal Medicine, AMITA Saint Francis Hospital, Evanston, IL, USA., Awadelkarim A; Department of Internal Medicine, Detroit Medical Center/Wayne State University, Detroit, MI, USA., Agab M; Department of Internal Medicine, AMITA Saint Francis Hospital, Evanston, IL, USA., Babkir A; Department of Internal Medicine, AMITA Saint Francis Hospital, Evanston, IL, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of medical cases [J Med Cases] 2022 Mar; Vol. 13 (3), pp. 135-139. Date of Electronic Publication: 2022 Mar 05. |
| DOI: | 10.14740/jmc3902 |
| Abstrakt: | Tocilizumab is a recombinant humanized monoclonal antibody directed against the interleukin-6 (IL-6) receptor, which has been used for the treatment of rheumatoid arthritis (RA). A range of side effects have been associated with tocilizumab, with gastrointestinal perforation (GIP) being described as a rare but potentially life-threatening complication that deserves considerable attention. The authors report a case of a young male patient with a history of challenging RA who encountered a lower GIP that was associated with tocilizumab therapy. The occurrence of tocilizumab-induced GIP in this reported patient had initially posed a diagnostic dilemma, as its clinical presentation mimicked other autoimmune inflammatory and infectious diseases that are commonly associated with RA. Physicians should be aware of GIPs as a serious adverse event of tocilizumab use despite being a rare phenomenon, particularly in the era of the global pandemic of coronavirus disease 2019 (COVID-19), when this novel drug has been authorized for the management of selected patients with severe COVID-19 infection. Therefore, early recognition and timely management of GIPs would minimize potential morbidities associated with critically ill COVID-19 patients. Competing Interests: The authors declare that they have no conflict of interest regarding the publication of this case report. (Copyright 2022, Saad et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|